Clinical Trials Logo

Clinical Trial Summary

This is a hypothesis-generating project to investigate a) infective etiology and b) inflammatory profile of the exacerbations of asthma in severe asthmatic patients treated with the humanized monoclonal antibody against interleukin-5 Mepolizumab. Under these treatment conditions the study will inform on the relationship between these two axes: infection & innate immunity Vs inflammatory profile changes occurring during exacerbation events. In addition, the study will also explore the effect of Mepolizumab treatment on airway microbial composition and on airway/systemic immune response both at stable state and at the exacerbation.


Clinical Trial Description

Longitudinal, observational study to evaluate the infective etiology and the inflammatory profile of asthma exacerbations in severe asthmatic patients treated (as part of routine medical care) with the humanized monoclonal antibody against interleukin-5 Mepolizumab. The participants receive Mepolizumab as part of routine medical care (see inclusion criteria). The study will assess the effect of the intervention (Mepolizumab) on airway microbial compositions and on airway/systemic inflammation at exacerbation and at stable state. The patients will be evaluated at baseline (the day of Mepolizumab initiation, before Mepolizumab administration - V0), at 1 month after Mepolizumab initiation (treatment visit - V1), at exacerbation (exacerbation visit - V2) and at 3 months after the exacerbation event (convalescence visit - V3) up to 12-month study period (Table 1). To perform the convalescence visit, a 3-month extension of the study period will be applied if the exacerbation occurs from month 9 to month 12 from the initiation of Mepolizumab. Recurrent exacerbation events will be evaluated separately when a paired-3-month convalescence visit can be performed within the study period. The patients will contact the center/researchers in case of worsening of the respiratory symptoms to schedule the exacerbation visit. The visit will be performed within 7 days from the beginning of the deterioration of the symptoms. At each visit, the following procedures will be performed in all the patients: 1) Clinical/pharmacological assessment (including assessment of asthma control; and measurements of central and peripheral fractional exhaled nitric oxide); 2) lung function tests (including lung volumes evaluation and small airway functional assessment by impulse oscillometry - IOS); 3) blood and sputum differential inflammatory cell counts; 4) sputum samples for microbiological assays (conventional sputum cultures and Multiplex Real Time PCR for virus and bacterial detection); 5) blood and sputum samples for cytokine profiling. In a representative subgroup of patients (n=30) breath condensate, blood and sputum samples will be performed for: 1) airway microbiome (16S ribosomal RNA Sequencing) evaluation; 2) blood innate immune responses; 3) transcriptomics and proteomics of sputum inflammatory cells; 4) breathomics. The study has been submitted for approval to the ethics committee, and informed written consent will be obtained from each enrolled subject. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04914078
Study type Observational
Source Università degli Studi di Ferrara
Contact Marco Contoli, MD
Phone +390532688148
Email ctm@unife.it
Status Recruiting
Phase
Start date September 21, 2021
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4
Active, not recruiting NCT06389058 - Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System